ASPS Recommends Delay for Youth Gender Surgeries

The American Society of Plastic Surgeons (ASPS) has updated its guidelines, advising that gender-affirming surgical procedures, including mastectomies, should generally be postponed until patients are at least 19 years old. This policy revision, announced in February 2026, reflects a reevaluation of the evidence supporting such interventions for minors.

This decision emerged after a significant meeting convened by Mehmet Oz, who leads the Centers for Medicare and Medicaid Services (CMS). S. medical society leaders to scrutinize the scientific basis for transgender medical care provided to adolescents.

During these discussions, Oz highlighted concerns regarding the lack of definitive long-term research on the effectiveness of various medical treatments, such as hormone therapy, puberty blockers, and surgical procedures, for young individuals experiencing gender dysphoria, particularly concerning their mental health trajectories.

Evidence Review and Policy Shift

The ASPS representative indicated that the society's internal review concluded that existing studies on the medical benefits of gender-affirming surgery for minors were insufficient and lacked robust quality. This assessment directly informed the new policy, which now recommends an age threshold for these specific surgical interventions.

The move by the ASPS marks a divergence from the established positions of some other major American medical organizations, such as the American Medical Association and the American Psychiatric Association, which have historically supported medical interventions for youth with gender dysphoria.

International Context and Broader Debate

This policy adjustment by the ASPS aligns with similar trends observed internationally. Several countries, including Britain, Finland, Sweden, and New Zealand, have recently implemented restrictions on medical treatments for transgender youth. These international shifts are largely driven by independent reviews that have also identified uncertainties and limited evidence regarding the long-term outcomes and efficacy of such medical interventions in younger populations.

Political and Medical Landscape

The broader discourse surrounding pediatric gender medicine in the United States is increasingly influenced by political considerations. The debate encompasses not only the medical efficacy and ethical implications of treatments but also societal and legislative perspectives on gender identity and healthcare access for minors.

This evolving landscape underscores a growing scrutiny of medical protocols and the need for more comprehensive, long-term research to inform clinical practice in this complex area of healthcare.

Future Implications for Care

The ASPS's updated guidance could prompt other medical societies to re-examine their own policies regarding gender-affirming care for minors. It also highlights the ongoing demand for more rigorous, longitudinal studies to better understand the effects of various interventions on the physical and psychological well-being of young people with gender dysphoria.

The medical community continues to navigate the balance between providing care and ensuring that interventions are based on the strongest possible evidence.

Implications

Country Impact: The policy shift could influence healthcare access and standards for transgender youth across the United States, potentially leading to similar reviews by other medical organizations. It also reflects a broader national debate on pediatric gender medicine.

Industry Impact: The medical and pharmaceutical industries involved in gender-affirming care may face increased scrutiny and demand for more robust clinical trial data, particularly for interventions targeting minors. This could impact product development and treatment protocols.

Market Impact: While direct market impact is limited, the policy change could affect healthcare providers specializing in gender-affirming care, potentially altering patient demographics and treatment pathways. It may also influence investment in research for long-term outcomes in this field.